News

Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company

NEW YORK and LONDON, Oct. 2, 2019 /PRNewswire/ — Health Sciences Acquisitions Corporation (“HSAC,”NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, and Immunovant Sciences Ltd. (“Immunovant”), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that they have entered into a definitive share exchange agreement (“SEA”). HSAC will acquire 100% …

Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company Read More »

Access our Annual Results 2019 Presentation Recording

  • This field is for validation purposes and should be left unchanged.